The Liraglutide Effects in Atrial Fibrillation (LEAF) Study.

Goldberger JJ, Mitrani RD, Fishman J, Zaatari G, Lowery M, Baez-Garcia C, Aguilar V, Blandon C, Hurwitz BE, Velasquez AH, Lambrakos LK, Dey D, Zarnegarnia Y, Iacobellis G

JACC. Clinical electrophysiology30 Mar 2026Cited by 2 (Europe PMC)

PMID42159524DOI10.1016/j.jacep.2026.03.026PepBankPUB-42159524

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight or obese patients with atrial fibrillation undergoing ablation, adding liraglutide to risk factor modification produced no between-group difference in left atrial epicardial adipose tissue reduction.
In plain wordsIn overweight or obese people with atrial fibrillation before ablation, liraglutide plus risk-factor care showed no difference in left atrial heart fat versus risk-factor care.
Peptide
Liraglutide
Outcome
No significant changeLeft atrial epicardial adipose tissue volume
Study
n = 59
Comparator
Risk factor modification
Analysis
Primary
Outcome group
Body composition · Cardiovascular
Studied dose
Dose not stated · 3 months preablationAs given in this study (human).
Source sentences
Summary
Overall, there were reductions in LAEAT (median -1.0 [Q1-Q3: -4.5 to 1.4] mL; P = 0.02) and weight (-2.8 ± 4.0 kg; P < 0.001) but no difference between groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In this randomized study of overweight/obese (body mass index ≥27 kg/m²) patients with AF (80% persistent AF) who opted for catheter ablation for treatment, 28 patients were assigned to RFM and 31 to risk factor modification (plus liraglutide (RFM+L) for 3 months preablation.
Summary · context
The primary endpoint was change in left atrial epicardial adipose tissue (LAEAT) volume.
Summary · context
One patient in the RFM group and 3 in the RFM+L group opted not to proceed with ablation, and "preablation" testing was performed at the time of this decision.
Report a problemFND-4215952401
02HumanRandomized controlled trialEfficacy outcome
In overweight or obese patients with atrial fibrillation undergoing ablation, risk-factor modification plus liraglutide achieved 81% freedom from atrial fibrillation or flutter at 12 months (95% CI 62%-91%) versus 54% with risk-factor modification alone (95% CI 34%-70%; log-rank P=0.007).
In plain wordsIn overweight or obese people with AF having ablation, liraglutide plus risk-factor care had more 12-month freedom from AF/flutter than care alone.
Peptide
Liraglutide
Outcome
IncreaseFreedom from atrial fibrillation or atrial flutter at 1 year
Study
n: not reported in source
Comparator
Risk factor modification
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 3 months preablationAs given in this study (human).
Measurements
Freedom from atrial fibrillation or flutter
81%
liraglutide plus risk-factor modification; 95% CI 62%-91%
Freedom from atrial fibrillation or flutter
54%
risk-factor modification; 95% CI 34%-70%; log-rank P=0.007
Source sentences
Summary
One-year freedom from AF/atrial flutter was 81% (95% CI: 62%-91%) for RFM+L and 54% (95% CI: 34%-70%) for RFM (log-rank P = 0.007).
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized study of overweight/obese (body mass index ≥27 kg/m²) patients with AF (80% persistent AF) who opted for catheter ablation for treatment, 28 patients were assigned to RFM and 31 to risk factor modification (plus liraglutide (RFM+L) for 3 months preablation.
Summary · context
Total EAT and recurrent AF at 1 year were secondary endpoints.
Report a problemFND-4215952403
03HumanRandomized controlled trialEfficacy outcome
In overweight or obese patients with atrial fibrillation undergoing ablation, RFM plus liraglutide was associated with lower 12-month recurrence than RFM alone in the LAEAT model (OR 0.19, 95% CI 0.05-0.73; P=0.015).
In plain wordsIn overweight or obese people with AF undergoing ablation, liraglutide plus risk-factor care was linked to lower recurrence than care alone, adjusting for LAEAT.
Peptide
Liraglutide
Outcome
DecreaseTwelve-month atrial fibrillation recurrence, LAEAT-adjusted model
Study
n: not reported in source
Comparator
Risk factor modification
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 3 months preablationAs given in this study (human).
Measurements
Odds ratio
0.19
RFM plus liraglutide versus RFM; LAEAT model; 95% CI 0.05-0.73; P=0.015
Source sentences
Summary
Logistic regression models showed RFM+L was associated with lower risk of 12-month recurrence (LAEAT model: OR: 0.19; 95% CI: 0.05-0.73; P = 0.015; EAT model: OR: 0.08; 95% CI: 0.01-0.40; P = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized study of overweight/obese (body mass index ≥27 kg/m²) patients with AF (80% persistent AF) who opted for catheter ablation for treatment, 28 patients were assigned to RFM and 31 to risk factor modification (plus liraglutide (RFM+L) for 3 months preablation.
Summary · context
Total EAT and recurrent AF at 1 year were secondary endpoints.
Report a problemFND-4215952404
04HumanRandomized controlled trialEfficacy outcome
In overweight or obese patients with atrial fibrillation undergoing ablation, RFM plus liraglutide was associated with lower 12-month recurrence than RFM alone in the EAT model (OR 0.08, 95% CI 0.01-0.40; P=0.002).
In plain wordsIn overweight or obese people with AF undergoing ablation, liraglutide plus risk-factor care was linked to lower recurrence than care alone, adjusting for EAT.
Peptide
Liraglutide
Outcome
DecreaseTwelve-month atrial fibrillation recurrence, EAT-adjusted model
Study
n: not reported in source
Comparator
Risk factor modification
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 3 months preablationAs given in this study (human).
Measurements
Odds ratio
0.08
RFM plus liraglutide versus RFM; EAT model; 95% CI 0.01-0.40; P=0.002
Source sentences
Summary
Logistic regression models showed RFM+L was associated with lower risk of 12-month recurrence (LAEAT model: OR: 0.19; 95% CI: 0.05-0.73; P = 0.015; EAT model: OR: 0.08; 95% CI: 0.01-0.40; P = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized study of overweight/obese (body mass index ≥27 kg/m²) patients with AF (80% persistent AF) who opted for catheter ablation for treatment, 28 patients were assigned to RFM and 31 to risk factor modification (plus liraglutide (RFM+L) for 3 months preablation.
Summary · context
Total EAT and recurrent AF at 1 year were secondary endpoints.
Report a problemFND-4215952407
05HumanRandomized controlled trialEfficacy outcome
In overweight or obese patients with atrial fibrillation undergoing ablation, adding liraglutide to risk factor modification produced no between-group difference in weight loss.
In plain wordsIn overweight or obese people with atrial fibrillation before ablation, liraglutide plus risk-factor care showed no weight difference versus risk-factor care.
Peptide
Liraglutide
Outcome
No significant changeWeight
Study
n = 59
Comparator
Risk factor modification
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 months preablationAs given in this study (human).
Source sentences
Summary
Overall, there were reductions in LAEAT (median -1.0 [Q1-Q3: -4.5 to 1.4] mL; P = 0.02) and weight (-2.8 ± 4.0 kg; P < 0.001) but no difference between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized study of overweight/obese (body mass index ≥27 kg/m²) patients with AF (80% persistent AF) who opted for catheter ablation for treatment, 28 patients were assigned to RFM and 31 to risk factor modification (plus liraglutide (RFM+L) for 3 months preablation.
Summary · context
One patient in the RFM group and 3 in the RFM+L group opted not to proceed with ablation, and "preablation" testing was performed at the time of this decision.
Report a problemFND-4215952402

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
Across both randomized groups of overweight or obese patients with atrial fibrillation, left atrial epicardial adipose tissue decreased by median 1.0 mL before ablation.
In plain wordsAcross both groups of overweight or obese people with atrial fibrillation, left atrial heart fat decreased before ablation.
Peptide
Liraglutide
Outcome
DecreaseOverall left atrial epicardial adipose tissue reduction
Study
n = 59
Analysis
Primary
Outcome group
Body composition · Cardiovascular
Measurements
LAEAT change
−1 mL
Q1-Q3 -4.5 to 1.4; P=0.02
Source sentences
Summary
Overall, there were reductions in LAEAT (median -1.0 [Q1-Q3: -4.5 to 1.4] mL; P = 0.02) and weight (-2.8 ± 4.0 kg; P < 0.001) but no difference between groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In this randomized study of overweight/obese (body mass index ≥27 kg/m²) patients with AF (80% persistent AF) who opted for catheter ablation for treatment, 28 patients were assigned to RFM and 31 to risk factor modification (plus liraglutide (RFM+L) for 3 months preablation.
Summary · context
The primary endpoint was change in left atrial epicardial adipose tissue (LAEAT) volume.
Summary · context
One patient in the RFM group and 3 in the RFM+L group opted not to proceed with ablation, and "preablation" testing was performed at the time of this decision.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4215952405
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
Across both randomized groups of overweight or obese patients with atrial fibrillation, weight decreased by 2.8 ± 4.0 kg before ablation.
In plain wordsAcross both groups of overweight or obese people with atrial fibrillation, weight decreased before ablation.
Peptide
Liraglutide
Outcome
DecreaseOverall weight reduction
Study
n = 59
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−2.8 kg
plus or minus 4.0; P<0.001
Source sentences
Summary
Overall, there were reductions in LAEAT (median -1.0 [Q1-Q3: -4.5 to 1.4] mL; P = 0.02) and weight (-2.8 ± 4.0 kg; P < 0.001) but no difference between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized study of overweight/obese (body mass index ≥27 kg/m²) patients with AF (80% persistent AF) who opted for catheter ablation for treatment, 28 patients were assigned to RFM and 31 to risk factor modification (plus liraglutide (RFM+L) for 3 months preablation.
Summary · context
One patient in the RFM group and 3 in the RFM+L group opted not to proceed with ablation, and "preablation" testing was performed at the time of this decision.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4215952406
08HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In overweight or obese patients with atrial fibrillation undergoing ablation, change in EAT density was associated with lower recurrence (OR 0.55, 95% CI 0.36-0.84; P=0.006).
In plain wordsIn overweight or obese people with atrial fibrillation having ablation, change in heart-fat density was linked to lower recurrence.
Peptide
Liraglutide
Outcome
DecreaseEAT-density change and recurrence
Study
n: not reported in source
Outcome group
Body composition · Cardiovascular
Measurements
Odds ratio
0.55
95% CI 0.36-0.84; P=0.006
Source sentences
Summary
Change in EAT density was associated with lower recurrence (OR: 0.55; 95% CI: 0.36-0.84; P = 0.006).
2 context sentences(design, population, supporting numbers)
Summary · context
In this randomized study of overweight/obese (body mass index ≥27 kg/m²) patients with AF (80% persistent AF) who opted for catheter ablation for treatment, 28 patients were assigned to RFM and 31 to risk factor modification (plus liraglutide (RFM+L) for 3 months preablation.
Summary · context
Total EAT and recurrent AF at 1 year were secondary endpoints.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4215952408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 4NCT03856632

Liraglutide Effect in Atrial Fibrillation

University of Miamin = 6018 Mar 2019 to est. 31 Dec 2026

Atrial Fibrillation

Trial page ClinicalTrials.govUpdated 1 May 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.